Concerns About Treatment of NHL Patients with 90Y-Ibritumomab Tiuxetan or 131I-Tositumomab
| Mean value* | |||
|---|---|---|---|
| Concern | Academia | Nonacademia | P (proportional odds) |
| There is no treatment site of 131I-tositumomab or 90Y-ibritumomab tiuxetan convenient for my patients | 1.608 | 2.418 | <0.01 |
| It is or would be economically adverse for my practice to use 131I-tositumomab or 90Y-ibritumomab tiuxetan | 1.775 | 2.209 | <0.01 |
| The nuclear physicians are not too interested in treating patients with 131I-tositumomab or 90Y-ibritumomab tiuxetan | 2.05 | 2.672 | <0.01 |
| Referring patients for 131I-tositumomab or 90Y-ibritumomab tiuxetan is too complicated | 2.138 | 2.724 | <0.01 |
| 131I-tositumomab or 90Y-ibritumomab tiuxetan do not have enough reported randomized studies | 2.45 | 2.343 | 0.8 |
| 131I-tositumomab or 90Y-ibritumomab tiuxetan is too expensive | 2.8 | 3.053 | 0.21 |
| There are possible unexpected late side effects (MDS) | 2.938 | 3.104 | 0.14 |
| 131I-tositumomab or 90Y-ibritumomab tiuxetan theoretically may cause bone marrow damage preventing further therapy (autologous stem cell transplantation) | 2.988 | 3.269 | 0.08 |
| There are too many effective nonradioactive treatment alternatives for the NHL | 3.013 | 2.993 | 0.98 |
↵* 1 = no concern; 5 = major concern, with P value indicating significant difference.